ARTICLE | Clinical News
BACE1 inhibitor: Phase I started
March 3, 2014 8:00 AM UTC
Boehringer began a Phase I trial of a BACE1 inhibitor. The start triggered a $14 million milestone payment to Vitae from Boehringer Ingelheim under a 2009 deal granting the pharma exclusive, worldwide...